Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma

Published:2019-03-15 Issue:6 Volume:58 Page:791-795
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Hirooka Masashi¹,Ochi Hironori²,Hiraoka Atsushi³,Koizumi Yohei¹,Matsuura Bunzo¹,Joko Kouji²,Michitaka Kojiro³,Abe Masanori¹,Hiasa Yoichi¹

Affiliation:

1. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan

2. Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Japan

3. Gastroenterology Center, Ehime Prefectural Central Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/6/58_1874-18/_pdf

Reference16 articles.

1. 1. Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52: 512-519, 2017.

2. 2. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465, 2008.

3. 3. Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747, 2014.

4. 4. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6: 18, 2014.

5. 5. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621-630, 2015.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world drug safety surveillance study of lenvatinib from the FAERS database;Expert Opinion on Drug Safety;2024-08-21

2. Systematic review of the efficacy and safety of lenvatinib in various solid tumors;Immunopharmacology and Immunotoxicology;2024-04-23

3. Subacute thyroiditis following COVID-19 vaccination: Case presentation;Antiviral Therapy;2023-10

4. Histological findings of thyroid cancer after lenvatinib therapy;Histopathology;2023-07-28

5. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study;Heliyon;2022-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3